Nyrada inc

Investor Presentation

October 2024

Improving Lives, Offering Hope

Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board.

ASX:NYR

Important Notice and Disclaimer

This presentation has been prepared by Nyrada Inc **("NYR"** or **"Company"**). It should not be considered as an offer or invitation to subscribe for, or purchase any securities in NYR, or as an inducement to purchase any securities in NYR. No agreement to subscribe for securities in NYR will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice, and the Company is not licensed to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements do not guarantee of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

About Nyrada

- Drug discovery and development company specialising in rational design of novel small molecule therapeutics.

- Nyrada's lead drug candidate NYR-BI03:
  - demonstrated strong preclinical efficacy protecting the brain from secondary injury following stroke.
  - demonstrated strong preclinical efficacy in protecting heart following acute myocardial-ischemic reperfusion injury.
  - preclinical TBI efficacy study with Walter Reed Army Institute of Research and UNSW in progress.
  - in advanced stages of Good Laboratory Practice safety and tolerability testing.

- Exploratory works for other indications and opportunities.

- Commercially focused business model and expert team.

Investment Proposition

- Pioneering transient receptor potential canonical (TRPC) channel blocking therapies.
- First-in-class neuroprotection therapy with novel mode of action.
- Cardioprotection therapy with superior performance to Captopril, an FDA approved ACE inhibitor.
- One drug asset targeting two significant therapeutic areas - neuroprotection and cardioprotection.
- Collaborations with world leading institutions: Walter Reed Army Institute of Research (WRAIR) and UNSW Sydney. Strategic partnership with Rebion.
- Proven and globally experienced board and team.
- Cash position of AU$4.77M at 30 June 2024.
  AU$0.99M R&D rebate expected around December 2024.

One Drug

NYR-BI03

GLP data package nearing completion

Approaching Phase I clinical trial in 4QCY2024

Two Applications

Neuroprotection

Cardioprotection

Three Markets

STROKE

~US$52.2 billion by 2032[2]

TRAUMATIC BRAIN INJURY

~US$5.5 billion by 2034[4]

MYOCARDIAL INFARCTION

~US$3.7 billion by 2032[5]

Neuroprotection – Stroke and TBI

Serial reconstruction from MRI





Nyrada drug NYR-BI03
An acute 3-day intravenous treatment

Reduce secondary injury resulting from stroke or TBI

- Improve survivability, limit disability
- Improve quality of life

Cardioprotection

Key Preclinical Results:



NYR-BI03 showed strong efficacy limiting cardiovascular damage associated with coronary heart disease

86%

Cardioprotection following myocardial ischemic-reperfusion injury

Superior efficacy

Compared to FDA-approved, Captopril



GLP Safety Studies Approaching Conclusion

GLP Study	Reported
AMES	16 July 2024
hERG	16 July 2024
Rat CNS	06 August 2024
Rat Respiratory	20 August 2024
Dog cardiovascular safety	09 September 2024
14-day dog toxicology	27 September 2024
14-day rat toxicology	
In vitro micronucleus	
In vivo micronucleus	

Near Term Catalysts

Early to Mid 4QCY2024
NYR-BI03 GLP study updates

Mid 4QCY2024
NYR-BI03 Human Research Ethics application submission

Late 4QCY2024
NYR-BI03 Phase I clinical trial

Early 1QCY2025
WRAIR TBI study update

Appendices

Indicative Phase I Study Design

OBJECTIVES To assess the safety, tolerability, and pharmacokinetics of NYR-BI03

DESIGN

- Randomised, double-blind placebo –controlled, dose escalation design
- 5 cohorts; 8 participants each cohort; 6:2 active and placebo treatments
- 3 cohorts will be single ascending doses
- 2 cohorts will be given continuous infusion doses

PARTICIPANTS

- Male and female healthy volunteers
- 18 – 50 years age



Active arm

Placebo

Cohort number	Dose administered
1	Low dose single bolus
2	Medium dose single bolus
3	High dose
4	Low dose continuous infusion (72 hrs)
5	High dose continuous infusion (72 hrs)

LOCATION & DURATION

- Study will be conducted at a clinical trial centre in Australia expected to commence 4QCY2024
- Study duration will vary between 1 – 4 days



*trial design subject to ethics approval

Large Market Opportunity – Stroke

Globally:

~15 million people suffer strokes annually[1]

~5 million left permanently disabled[1]

One approved drug class for stroke suitable for <15% of patients (tPA - tissue plasminogen activator).

Effective treatment will improve patient outcomes and reduce high costs associated with long-term care.

Large and growing treatment market:

Currently **~US$30.3 billion[2]**

Growing **~7.5% CAGR[2]**

Forecast **~US$52.2 billion by 2030[2]**

Large Market Opportunity – Traumatic Brain Injury (TBI)

Globally:

~5.5 million people suffer severe TBA annually[3]

~55 million living with effects of medically treated TBI[3]

No current FDA approved treatments

Effective treatment will improve patient outcomes and reduce high costs associated with long-term care of brain injury survivors.

Large and growing treatment market:

Currently **~US$3.5 billion[4]**

Growing **~6.2% CAGR[4]**

Forecast **~US$5.5 billion by 2030[4]**



Nyrada's Lead Drug Candidate NYR-BI03

First-in-Class with Novel Mechanism of Action

- NYR-BI03 is a first-in-class therapy.
- Novel mechanism of action.
- Australian developed innovation.

Significant Unmet Clinical Need and Market Opportunity

- Targeting multiple indications.
- Stroke, TBI and Cardiac heart disease are leading causes of death and disability.
- No current FDA approved drugs to treat secondary brain injury.

Management Team with Proven Industry Experience

James Bonnar - CEO

- Business executive with 25 years of experience in healthcare companies in the UK, China, New Zealand, and Australia
- Experience in drug manufacture, preclinical development, clinical operations, regulatory affairs, and quality assurance
- Biotech experience spanning various therapeutic areas including cardiometabolic disease, neurodevelopment disorders, and brain injury

Cameron Jones - CFO

- Finance executive with experience as CFO and Company Secretary of ASX Listed and VC investee healthcare companies
- Supported several healthcare companies through IPOs, capital raisings and M&A transactions
- Managing Director of Bio101, financial services firm
- Chartered Accountant, Member of the Governance Institute of Australia and Registered Tax Agent

Dr Benny Evison - CSO

- More than 20 years of experience in the discovery and development of small molecule inhibitors as therapies for various cancers, cardiovascular diseases and neurodegenerative diseases
- Obtained a PhD at La Trobe University (Melbourne, Australia) in biochemistry and molecular biology, and a postdoctoral fellowship in chemical biology at St Jude Children's Research Hospital, (Memphis TN)

Supported by specialist advisers:

- **Prof Gary Housley**
  Brain injury program
- **Prof Junichi Nabekura**
  Brain injury program
- **Dr Jim Palmer**
  Medicinal Chemist
- **Dr Mike Bickerdike**
  Toxicologist

High Calibre Board with international experience

- Nyrada operates under the direction of a governing board of international calibre
- Strong track record in realising the value of biotech companies
- Experience in dealmaking, US/EU/AU capital markets, and relevant therapeutic area experience

John Moore
Non-Executive Chair

Dr Ian Dixon
Non-Executive Director

Dr Gisela Mautner
Non-Executive Director

Marcus Frampton
Non-Executive Director

Dr Rüdiger Weseloh
Non-Executive Director

Christopher Cox
Non-Executive Director

References

1 – World Health Organization - https://www.emro.who.int/health-topics/stroke-cerebrovascular-accident/index.html#:~:text=Annually%2C%2015%20million%20people%20worldwide,cause%20is%20high%20blood%20pressure

2 – Databridge Market Research - https://www.databridgemarketresearch.com/reports/global-stroke-market .

3 – National Academy of Sciences - https://nap.nationalacademies.org/catalog/25394/traumatic-brain-injury-a-roadmap-for-accelerating-progress

4 – Databridge Market Research - https://www.databridgemarketresearch.com/reports/global-traumatic-brain-injuries-treatment-market

5 – Spherical Insights – https://www.globenewswire.com/en/news-release/2023/05/30/2678779/0/en/Global-Myocardial-Infarction-Market-Size-To-Grow-USD-3-7-Billion-By-2032-CAGR-of-6-8.html



Brain Injury
Solution Animation



Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board.